Ameliorating the antimicrobial resistance crisis: phage therapy
- 23 January 2019
- journal article
- review article
- Published by Wiley in IUBMB Life
- Vol. 71 (7) , 781-790
Abstract
Propelled by the overuse and inappropriate use of antibiotics, antimicrobial resistance is now widespread in the environment, leaving us with limited drugs for treating a large number of resistant pathogens. The use of bacteriophages that kill bacteria has come up as a viable alternative to circumvent the antimicrobial resistance crisis, and phage therapy‐based approaches are fast advancing in recent times. In this minireview, we try to describe the advantages associated with phage therapy and update the latest developments in the field including the clinical trials that are underway. Particularly, we highlight the synergistic bactericidal effect of phages in the presence of sub‐lethal dose of antibiotics and the potency of lytic phages, and their hydrolytic enzymes in expunging pathogens from drug‐tolerant biofilms and animal farm produce. We also discuss how major challenges, including human immune response to phage components, development of bacterial resistance and elimination of intracellular pathogens, presented as potential setbacks to the implementation of phage therapy is being removed using engineered phages and novel formulations. © 2019 IUBMB Life, 2019Keywords
Funding Information
- Department of Biotechnology, Government of West Bengal
- Anusandhan National Research Foundation
This publication has 107 references indexed in Scilit:
- Tracking Change: A Look at the Ecological Footprint of Antibiotics and Antimicrobial ResistanceAntibiotics, 2013
- Efficacy of Bacteriophage Therapy in Experimental Sepsis and Meningitis Caused by a Clone O25b:H4-ST131 Escherichia coli Strain Producing CTX-M-15Antimicrobial Agents and Chemotherapy, 2012
- Experimental Phage Therapy in TreatingKlebsiella pneumoniae-Mediated Liver Abscesses and Bacteremia in MiceAntimicrobial Agents and Chemotherapy, 2011
- Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteriaApplied Microbiology and Biotechnology, 2011
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- Characterization of a New Metallo-β-Lactamase Gene, bla NDM-1 , and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from IndiaAntimicrobial Agents and Chemotherapy, 2009
- Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapyProceedings of the National Academy of Sciences, 2009
- Experimental Phage Therapy against Staphylococcus aureus in MiceAntimicrobial Agents and Chemotherapy, 2007
- Dispersing biofilms with engineered enzymatic bacteriophageProceedings of the National Academy of Sciences, 2007
- Using Bacteriophages To Reduce Formation of Catheter-Associated Biofilms byStaphylococcus epidermidisAntimicrobial Agents and Chemotherapy, 2006